Tags

Type your tag names separated by a space and hit enter

Lipoxins and new lipid mediators in the resolution of inflammation.
Curr Opin Pharmacol. 2006 Aug; 6(4):414-20.CO

Abstract

Lipoxins and aspirin-triggered lipoxins are lipid mediators generated from arachidonic acid that act to reduce inflammation and promote resolution. In addition, two new families of lipid mediators were uncovered, namely resolvins (resolution phase interaction products) and protectins, which derive from omega-3 polyunsaturated fatty acid. They possess potent anti-inflammatory, neuroprotective and pro-resolving properties. Eicosapentaenoic acid-derived mediators are denoted resolvins of the E series, and those biosynthesized from docosahexaenoic acid are resolvins of the D series (RvDs) and protectins. Aspirin impinges on these systems, triggering formation of the epimeric 17R-series RvDs--denoted as 'aspirin-triggered-RvDs'--which possess bioactivity in vivo equivalent to that evoked by their 17S-series counterparts (i.e. RvDs). These bioactive molecules open new avenues and approaches to therapeutic interventions via accelerated resolution of inflammation.

Authors+Show Affiliations

Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, 75 Francis Street, Boston MA 02115, USA.No affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

16750421

Citation

Schwab, Jan M., and Charles N. Serhan. "Lipoxins and New Lipid Mediators in the Resolution of Inflammation." Current Opinion in Pharmacology, vol. 6, no. 4, 2006, pp. 414-20.
Schwab JM, Serhan CN. Lipoxins and new lipid mediators in the resolution of inflammation. Curr Opin Pharmacol. 2006;6(4):414-20.
Schwab, J. M., & Serhan, C. N. (2006). Lipoxins and new lipid mediators in the resolution of inflammation. Current Opinion in Pharmacology, 6(4), 414-20.
Schwab JM, Serhan CN. Lipoxins and New Lipid Mediators in the Resolution of Inflammation. Curr Opin Pharmacol. 2006;6(4):414-20. PubMed PMID: 16750421.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lipoxins and new lipid mediators in the resolution of inflammation. AU - Schwab,Jan M, AU - Serhan,Charles N, Y1 - 2006/06/05/ PY - 2006/02/03/received PY - 2006/02/03/accepted PY - 2006/6/6/pubmed PY - 2006/12/9/medline PY - 2006/6/6/entrez SP - 414 EP - 20 JF - Current opinion in pharmacology JO - Curr Opin Pharmacol VL - 6 IS - 4 N2 - Lipoxins and aspirin-triggered lipoxins are lipid mediators generated from arachidonic acid that act to reduce inflammation and promote resolution. In addition, two new families of lipid mediators were uncovered, namely resolvins (resolution phase interaction products) and protectins, which derive from omega-3 polyunsaturated fatty acid. They possess potent anti-inflammatory, neuroprotective and pro-resolving properties. Eicosapentaenoic acid-derived mediators are denoted resolvins of the E series, and those biosynthesized from docosahexaenoic acid are resolvins of the D series (RvDs) and protectins. Aspirin impinges on these systems, triggering formation of the epimeric 17R-series RvDs--denoted as 'aspirin-triggered-RvDs'--which possess bioactivity in vivo equivalent to that evoked by their 17S-series counterparts (i.e. RvDs). These bioactive molecules open new avenues and approaches to therapeutic interventions via accelerated resolution of inflammation. SN - 1471-4892 UR - https://www.unboundmedicine.com/medline/citation/16750421/Lipoxins_and_new_lipid_mediators_in_the_resolution_of_inflammation_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1471-4892(06)00088-9 DB - PRIME DP - Unbound Medicine ER -